Molnupiravir licensed

October 27, 2021

Vaccines have been the standout case where people say, ‘This isn’t fair with what’s happening.’ This is now a step to correcting some of that.

Executive Director Charles Gore, Medicines Patent Pool, on Merck licensing its new COVID-19 pill to the nonprofit.
  • Medicines Patent Pool is a nonprofit backed by the UN.
  • By sharing its license for molnupiravir with this group, Merck essentially gives the nonprofit permission to make the treatment. The nonprofit will then find drug makers to produce it for middle- and low-income countries.
  • Molnupiravir is provided in pill form and taken at home – unlike other treatments, such as monoclonal antibody treatment or remdesivir, which require direct medical supervision and intravenous therapy.
  • Why It Matters: A recent report suggested molnupiravir was effective in preventing hospitalization/severe cases of COVID-19. The hope is that the more people are given access to it, the fewer there are who will get severely ill.

Promising Covid-19 Pill Licensed to U.N.-Backed Nonprofit to Increase Global Supplies

by Jenna Lee,